The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.’s (NASDAQ:GH) Guardant360 Liquid CDx test, expanding the company's blood-based comprehensive genomic profiling capabilities for patients with advanced cancer.
The approval also transfers the seven previously approved companion diagnostic indications from Guardant360 CDx to the updated test.
Something went wrong.
The cancer testing company said Guardant360 Liquid CDx is now the largest FDA-approved liquid biopsy panel and evaluates a genomic footprint that is 100 times wider than the earlier Guardant360 CDx test.
The test combines genomic and epigenomic insights from a single blood sample to help clinicians make more informed treatment decisions.
